How molecularly similar are primary and metastatic tissues in renal cell carcinoma? - Authors' reply

Yann-Alexandre Vano¹, Réza Elaidi², Letuan Phan², Maxime Meylan³, Wolf Herman Fridman³, Catherine Sautès-Fridman³, Stéphane Oudard⁴; BIONIKK co-investigators

Affiliations

¹ Department of Medical Oncology, Université de Paris Citeé, Paris, France; Hoôpital Europeéen Georges Pompidou, Institut du Cancer Paris, CARPEM, AP-HP Centre, Université de Paris Citeé, Paris, France; Centre de Recherche des Cordeliers, INSERM, Université de Paris Citeé, Sorbonne Université, Paris, France; INSERM U970, PARCC, Paris, France. Electronic address: yann.vano@aphp.fr.
² ARTIC-Association pour la Recherche de Theérapeutiques Innovantes en Canceérologie, Université de Paris Citeé, Paris, France.
³ Centre de Recherche des Cordeliers, INSERM, Université de Paris Citeé, Sorbonne Université, Paris, France.
⁴ Department of Medical Oncology, Université de Paris Citeé, Paris, France; Hoôpital Europeéen Georges Pompidou, Institut du Cancer Paris, CARPEM, AP-HP Centre, Université de Paris Citeé, Paris, France; INSERM U970, PARCC, Paris, France.

PMID: 35772459
DOI: 10.1016/S1470-2045(22)00344-8

Comment

How molecularly similar are primary and metastatic tissues in renal cell carcinoma? - Authors' reply

Yann-Alexandre Vano et al. Lancet Oncol. 2022 Jul.

. 2022 Jul;23(7):e317.

doi: 10.1016/S1470-2045(22)00344-8.

Authors

Yann-Alexandre Vano¹, Réza Elaidi², Letuan Phan², Maxime Meylan³, Wolf Herman Fridman³, Catherine Sautès-Fridman³, Stéphane Oudard⁴; BIONIKK co-investigators

Affiliations

¹ Department of Medical Oncology, Université de Paris Citeé, Paris, France; Hoôpital Europeéen Georges Pompidou, Institut du Cancer Paris, CARPEM, AP-HP Centre, Université de Paris Citeé, Paris, France; Centre de Recherche des Cordeliers, INSERM, Université de Paris Citeé, Sorbonne Université, Paris, France; INSERM U970, PARCC, Paris, France. Electronic address: yann.vano@aphp.fr.
² ARTIC-Association pour la Recherche de Theérapeutiques Innovantes en Canceérologie, Université de Paris Citeé, Paris, France.
³ Centre de Recherche des Cordeliers, INSERM, Université de Paris Citeé, Sorbonne Université, Paris, France.
⁴ Department of Medical Oncology, Université de Paris Citeé, Paris, France; Hoôpital Europeéen Georges Pompidou, Institut du Cancer Paris, CARPEM, AP-HP Centre, Université de Paris Citeé, Paris, France; INSERM U970, PARCC, Paris, France.

PMID: 35772459
DOI: 10.1016/S1470-2045(22)00344-8

No abstract available

PubMed Disclaimer

Conflict of interest statement

Y-AV has received research funding from Bristol Myers Squibb (BMS) and Ipsen (all fees for his institution); has been on an advisory board or data safety monitoring board for BMS and Roche; has received honoraria for lectures and presentations from BMS, MSD, Ipsen, Merck, Pfizer, Roche, Novartis, Janssen, Astellas, and Viatris; and has received support for travel or meetings from BMS, MSD, Pfizer, Ipsen, and Roche. SO has received consultancy fees from BMS and Pfizer; and honoraria for lectures or presentations from BMS and Pfizer. All other authors declare no competing interests.

Comment on

Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.
Vano YA, Elaidi R, Bennamoun M, Chevreau C, Borchiellini D, Pannier D, Maillet D, Gross-Goupil M, Tournigand C, Laguerre B, Barthélémy P, Coquan E, Gravis G, Houede N, Cancel M, Huillard O, Beuzeboc P, Fournier L, Méjean A, Cathelineau X, Doumerc N, Paparel P, Bernhard JC, de la Taille A, Bensalah K, Tricard T, Waeckel T, Pignot G, Braychenko E, Caruso S, Sun CM, Verkarre V, Lacroix G, Moreira M, Meylan M, Bougouïn A, Phan L, Thibault-Carpentier C, Zucman-Rossi J, Fridman WH, Sautès-Fridman C, Oudard S. Vano YA, et al. Lancet Oncol. 2022 May;23(5):612-624. doi: 10.1016/S1470-2045(22)00128-0. Epub 2022 Apr 4. Lancet Oncol. 2022. PMID: 35390339 Clinical Trial.
How molecularly similar are primary and metastatic tissues in renal cell carcinoma?
Kahya BU, Sütcüoğlu O, Özdemir N, Yazıcı O. Kahya BU, et al. Lancet Oncol. 2022 Jul;23(7):e316. doi: 10.1016/S1470-2045(22)00330-8. Lancet Oncol. 2022. PMID: 35772458 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

How molecularly similar are primary and metastatic tissues in renal cell carcinoma? - Authors' reply

Affiliations

How molecularly similar are primary and metastatic tissues in renal cell carcinoma? - Authors' reply

Authors

Affiliations

Conflict of interest statement

Comment on

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical